News Conference News TVT 2017 Volume Underload? More TAVRs Done, the Better the Operator Outcomes, Yet Many Patients Go Untreated Michael O'Riordan June 16, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017